SH
Therapeutic Areas
Optimeos Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Hepatic Gene Replacement | Citrullinemia Type 1 | Pre-clinical |
| In Vivo T Cell Engineering | Autoimmune Diseases & Cancer | Research |
| Long-acting GLP-1 Depot | Obesity/Metabolic Diseases | Pre-clinical |
Leadership Team at Optimeos Life Sciences
BP
Bob Prud'homme, PhD
CoFounder and CTO
GH
Gregory Harriman, MD
CMO
JS
Jason Smith, PhD
HEAD OF BUSINESS DEVELOPMENT
RP
Rob Pagels, PhD
Senior Director of R&D
CM
Chet Markwalter, PhD
SENIOR DIRECTOR OF SCIENTIFIC OPERATIONS
ME
Mark Esposito, PhD
Senior Director of Biology